AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB▲

Laughing Water Capital Adds AnaptysBio as New Position, Sees Potential 50-80% Upside

Laughing Water Capital added AnaptysBio as a new position in the second quarter of 2026, citing a special situation that could resolve quickly. Following a taxable spinoff of its developmental drug assets, AnaptysBio is now an asset-light royalty company collecting payments on sales of Jemperli, a cancer drug commercialized by GSK. The firm believes it purchased shares at a discount to the present value of future royalties, but sees additional upside from a trial set for July 14-17 in which AnaptysBio accuses GSK of violating their commercial agreement. If AnaptysBio prevails, it could recover the entirety of Jemperli, potentially pushing shares to nearly $300 versus an average purchase price below $60. A more likely scenario, according to Laughing Water Capital, is a settlement or outright acquisition by GSK, which could yield 50 to over 80 percent upside.

ANAB ▲GSK.LSE ▼

Insider Monkey·43dRead more ▾